Pre-earnings options volume in Corcept Therapeutics is 6.4x normal with calls leading puts 10:3. Implied volatility suggests the market is anticipating a move near 9.8%, or $3.52, after results are released. Median move over the past eight quarters is 6.0%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Is CORT a Buy, Before Earnings?
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept presents results from prevalence phase of CATALYST at ADA
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
- Corcept Therapeutics weakness a buying opportunity, says Canaccord